AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase II clinical study titled ‘DESTINY PanTumor03.’ The study aims to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) as a monotherapy or in combination with other anti-cancer agents for treating patients with selected HER2-expressing tumors. This research is significant as it targets locally advanced, unresectable, or metastatic tumors that are not eligible for curative therapy.
The study tests Trastuzumab Deruxtecan, an intravenous drug, both alone and combined with Bevacizumab, another intravenous drug. The purpose is to assess their effectiveness in treating various HER2-expressing solid tumors, excluding breast and gastric cancers.
The study design is interventional, non-randomized, and open-label, meaning all participants and researchers know the treatment being administered. It follows a parallel intervention model with the primary goal of treatment.
Key dates for the study include its start on February 18, 2024, and the latest update on August 8, 2025. These timelines are crucial for tracking the study’s progress and potential impact on treatment options.
This clinical update could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance investor confidence and market positioning in the oncology sector. Competitors in the HER2-targeted therapy space will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.